Wetenschappelijke publicaties van Bordet

Wetenschappelijke publicaties van Bordet

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.

Brandão M, Prisciandaro E, Xenophontos E, Mariolo A, Sadeghi AH, Filippi AR, Levy A, Bandura A, Caramella C, Dickhoff C, de Margerie-Mellon C, Faivre-Finn C, Portik D, Sanchez-Lorente D, De Ruysscher D, Smit E, Gobbini E, Fadel E, Ruffini E, Olmetto E, Cortiula F, Bahce I, Houda I, Opitz I, Naidoo J, Edwards J, Remon J, Benitez JC, Trujillo JC, Derks J, Amrane K, Hartemink KJ, Stathopoulos K, Hendriks LEL, Iglesias M, Occhipinti M, Guckenberger M, Giaj Levra N, Girard N, Reguart N, Mercier O, Bironzo P, Hofman P, Petersen RH, De Angelis R, Abgral R, Terrisse S, Popat S, Pierret T, Blum TG, Ricardi U, Dionisi V, Berghmans T, Dingemans AC

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.

Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).

Malorni L, Tyekucheva S, Gombos A, Hasler-Strub U, Zamagni C, Chakiba-Brugère C, Colleoni M, Mueller A, Minisini AM, Taylor D, Salmon JP, Gallerani E, Cariello A, Fontana A, Roschitzki-Voser H, Kammler R, Ruepp B, Loi S, Viale G, Regan MM, Brain E, Biganzoli L

Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

Moreau P, Hulin C, Talbot A, Demarquette H, Caillot L, Chalopin T, Bobin A, Manier S, Leleu X, Karlin L, Caillot D, Sonntag C, Feugier P, Roussel M, Gounot R, Macro M, Mohty M, Garderet L, Tiab M, Orsini-Piocelle F, Vincent L, Meuleman N, Fontan J, Montes L, Vekemans MC, Escoffre-Barbe M, Eveillard JR, Schiano de Colella JM, Lambert J, Mary JY, Fermand JP, Arnulf B, Corre J, Avet-Loiseau H, Facon T, Harousseau JL, Touzeau C, Perrot A

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

Digital and AI-assisted multimodal supportive care, combining physical activity, nutrition, and pain management during chemotherapy for advanced pancreatic cancer patients: study protocol of the European multicenter randomized controlled trial of the RELEVIUM project.

Hillen B, Oestreicher G, Schwab L, Enders K, Simon P, Elme A, Ben-Aharon I, Goshenlago T, Neuzillet C, Sclafani F, Beltran EEM, Schuster M, Doncheva H, Ruckes C, Karlecik M, Petrowski K, Rosenbaum D, Diou C, Ballas A, Vlachostergiou A, Mastricci D, Scherrer A, Pilz M, Flechsig J, Apostolidis L, Krooupa AM, Chintha S, Musisi IW, Tzavara NP, Kakasis A, Hadjikypri X, Karra S, Chatzipanagiotou K, Drivas I, Dacasa H, Moehler M

Digital and AI-assisted multimodal supportive care, combining physical activity, nutrition, and pain management during chemotherapy for advanced pancreatic cancer patients: study protocol of the European multicenter randomized controlled trial of the RELEVIUM project.

The role of body mass index at diagnosis in patients with inflammatory breast cancer.

Borremans K, Nguyen HL, De Schepper M, Lerebours F, Vion R, Clatot F, Berghian A, Maetens M, Isnaldi E, Molinelli C, Lambertini M, Grillo F, Zoppoli G, Dirix L, Punie K, Wildiers H, Smeets A, Nevelsteen I, Neven P, Vincent-Salomon A, Larsimont D, Duhem C, Viens P, Bertucci F, Biganzoli E, Vermeulen P, Floris G, Richard F, Desmedt C

The role of body mass index at diagnosis in patients with inflammatory breast cancer.

Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world study.

Alouani E, Taieb J, Tougeron D, Roces G, Hollebecque A, Parent P, Pernot S, Sinicrope FA, Hautefeuille V, Ben-Abdelghani M, Dutherage M, Cohen R, Hafliger E, Sclafani F, Muller M, Perkins G, Masson T, Aparicio T, Coutzac C, Mazard T, Decraecker M, Jaffrelot M, Guimbaud R, Selves J

Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world study.
Erasme hospital

Erasmusziekenhuis

Bekijk alle wetenschappelijke publicaties van Erasmus

Wetenschappelijke publicaties van Erasmus
Huderf hospital

Queen Fabiola Kinderziekenhuis

Bekijk alle wetenschappelijke publicaties van het Koningin Fabiola Kinderziekenhuis

Wetenschappelijke publicaties van het Koningin Fabiola-Kinderziekenhuis
Bordet hospital

Jules Bordet-instituut

Bekijk alle wetenschappelijke publicaties van Jules Bordet

Wetenschappelijke publicaties van Jules Bordet